Wegovy HD adds a 7.2 mg dose at about $399 a month
A higher-dose option for patients who plateau at the 2.4 mg maintenance dose, priced through the manufacturer channel.
Novo Nordisk added a higher-dose Wegovy option at 7.2 mg, reported at around $399 a month through its direct pharmacy channel, aimed at patients who have plateaued at 2.4 mg.
The standard ladder tops out at 2.4 mg, and patients who stall there have historically had two options: accept the plateau or switch molecule. A higher dose is a third.
Compounded programmes do not offer this dose, and a compounded preparation is not FDA-approved.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement or the clinical review behind a prescription.
Where a development moves a figure we publish, the change is recorded with its date on our methodology page rather than edited in silently.
How to verify this yourself
Regulatory claims should be checked against the agency rather than coverage of the agency. FDA publishes warning letters searchable by company name and a drug shortage database, both free and both more current than any summary.